Group 1 - The core viewpoint of the news is that Chutian Technology's stock has seen a significant increase of 6.07%, reaching a price of 11.88 CNY per share, with a trading volume of 381 million CNY and a turnover rate of 5.75%, resulting in a total market capitalization of 7.013 billion CNY [1] - Chutian Technology Co., Ltd. is located in Changsha, Hunan Province, and was established on November 8, 2002, with its listing date on January 21, 2014. The company's main business involves pharmaceutical equipment and comprehensive technical solutions [1] - The revenue composition of Chutian Technology includes: testing and packaging solutions (24.88%), parts and after-sales service (16.44%), bioengineering solutions (14.84%), sterile preparation solutions (14.61%), pharmaceutical water equipment and engineering system integration (13.81%), solid preparation solutions (10.85%), EPC engineering design services (3.57%), other products (0.73%), and others (0.28%) [1] Group 2 - Anxin Fund has a fund that ranks among the top ten circulating shareholders of Chutian Technology. The Anxin Medical Health Stock A (010709) fund entered the top ten circulating shareholders in the third quarter, holding 1.7338 million shares, which accounts for 0.3% of the circulating shares. The estimated floating profit today is approximately 1.179 million CNY [2] - The Anxin Medical Health Stock A (010709) fund was established on January 12, 2021, with a latest scale of 413 million CNY. Year-to-date returns are 62.45%, ranking 245 out of 4216 in its category; the one-year return is 52.89%, ranking 478 out of 3894; and since inception, the return is 55.12% [2]

Group 1 - Han Yu Pharmaceutical (300199.SZ) released its semi-annual report for 2025 on August 22, 2025 [1] - As of August 21, 2025, seven institutional investors disclosed holdings in Han Yu Pharmaceutical A-shares, totaling 44.3541 million shares, which accounts for 5.02% of the company's total share capital [1] - The institutional investors include Shenzhen High-tech Investment Group Co., Ltd., Hong Kong Central Clearing Limited, and others, with a total institutional holding ratio decreasing by 1.61 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, two public funds reduced their holdings compared to the previous quarter, including Bosera CSI Taogold Big Data 100 A and China Merchants Stable Growth Mixed A, with a slight decrease in holding ratio [1] - One insurance fund increased its holdings, specifically Fude Property Insurance Co., Ltd. - proprietary funds, with an increase of 0.1% [1] - Foreign investment sentiment showed a decrease in holdings from one foreign fund, Hong Kong Central Clearing Limited, with a slight decline in holding ratio compared to the previous quarter [1]

Group 1 - Warner Pharmaceutical has experienced a decline for five consecutive trading days, with a cumulative drop of -10.00% [1] - Founded in 2001, Hunan Warner Pharmaceutical Co., Ltd. was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in 2021 (stock code: 688799) and operates as an innovative drug manufacturing company covering traditional Chinese medicine, chemical drugs, and biopharmaceuticals [1] - Anxin Fund's Anxin Medical Health Stock A is among the top ten shareholders of Warner Pharmaceutical and has reduced its holdings in the second quarter of this year, achieving a year-to-date return of 69.42%, ranking 18th among 915 similar funds [1] Group 2 - The fund manager of Anxin Medical Health Stock A is Chi Chenshen, who holds a master's degree in economics and has previously worked as a researcher at various financial institutions [2][3] - Chi Chenshen has been managing the Anxin Medical Health Stock A fund since January 12, 2021, with a current fund size of 4.42 billion and a return of 65.80% during his tenure [3] - Anxin Fund Management Co., Ltd. was established in December 2011, with major shareholders including WISCO Capital Holdings Co., Ltd. (39.84%) and Guotou Securities Co., Ltd. (33.95%) [3]

Group 1 - Huakang Clean (301235.SZ) released its semi-annual report for 2025 on July 30, 2025, with 10 institutional investors holding a total of 19.8267 million shares, accounting for 18.78% of the total share capital [1] - The top ten institutional investors include Sunshine Life Insurance Co., Ltd. - Dividend Insurance Product, Wuhan Kanghui Investment Management Center (Limited Partnership), and several others, with their combined holding ratio increasing by 0.56 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, Nuon An Multi-Strategy Mixed A, increased its holdings by 0.20%, while two new public funds were disclosed, including Anxin Medical Health Stock A and China Merchants CSI 1000 Index Enhanced A [2] - In the insurance capital sector, Sunshine Life Insurance Co., Ltd. - Dividend Insurance Product reduced its holdings by 1.0% compared to the previous quarter [2] - Three new foreign institutional investors were disclosed, including BARCLAYS BANK PLC, J.P. Morgan Securities PLC - proprietary funds, and Goldman Sachs LLC [2]